Sangui Biotech International Stock Fundamentals
| SGBI Stock | USD 0 0.00 0.00% |
Sangui Biotech International fundamentals help investors to digest information that contributes to Sangui Biotech's financial success or failures. It also enables traders to predict the movement of Sangui Pink Sheet. The fundamental analysis module provides a way to measure Sangui Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangui Biotech pink sheet.
Sangui |
Sangui Biotech International Company Return On Asset Analysis
Sangui Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Sangui Biotech Return On Asset | -0.64 |
Most of Sangui Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangui Biotech International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Sangui Biotech International has a Return On Asset of -0.6411. This is 92.67% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Sangui Biotech Inter Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sangui Biotech's current stock value. Our valuation model uses many indicators to compare Sangui Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sangui Biotech competition to find correlations between indicators driving Sangui Biotech's intrinsic value. More Info.Sangui Biotech International is rated fourth in return on asset category among its peers. It is rated second in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sangui Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sangui Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Sangui Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangui Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sangui Biotech could also be used in its relative valuation, which is a method of valuing Sangui Biotech by comparing valuation metrics of similar companies.Sangui Biotech is currently under evaluation in return on asset category among its peers.
Sangui Fundamentals
| Return On Asset | -0.64 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.50) % | |||
| Current Valuation | 1.68 M | |||
| Shares Outstanding | 209.9 M | |||
| Shares Owned By Insiders | 13.03 % | |||
| Price To Earning | (18.33) X | |||
| Price To Book | 46.44 X | |||
| Price To Sales | 10.09 X | |||
| Revenue | 69.19 K | |||
| Gross Profit | 69.19 K | |||
| EBITDA | (18.44 K) | |||
| Net Income | (63.34 K) | |||
| Cash And Equivalents | 30.47 K | |||
| Total Debt | 48.9 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (140.46 K) | |||
| Beta | 0.22 | |||
| Market Capitalization | 902.58 K | |||
| Total Asset | 130.79 K | |||
| Retained Earnings | (37 M) | |||
| Net Asset | 130.79 K |
About Sangui Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangui Biotech International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangui Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangui Biotech International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.